Abstract
A series of new C-3 and N1-substituted 4-fluorotryptamides have been prepared and tested for their ability to activate pigment granule aggregation in Xenopus laevis melanophores and bind to the recombinant human MT1 and MT2 melatonin receptor subtypes expressed in NIH 3T3 cells. Planar sp2 geometry at C-3-βC seems to decrease the population of the preferred conformation as it renders 4-fluoroindoles 4b-d weaker antagonists than their C-3-βC-unsubstituted congeners 3a-e. This effect is not preclusively linked with the C-3 region, as the same geometry around N1 (compounds 5a-c) similarly leads to weak antagonistic action. Last, the new C-3 substituted 4-fluorotryptamides presented herein are substantially more potent than their respective N-OMe functionalized congeners, previously reported.
Keywords: Substituted 4-fluoroindoles, synthesis, melatoninergic activity
Current Drug Discovery Technologies
Title: Design and Synthesis of New N1 and C3-Substituted 4-Fluoroindolic Melatoninergics
Volume: 4 Issue: 3
Author(s): Andrew Tsotinis, Andreas Eleutheriades, Kathryn Davidson, David Sugden, Andrew Tsotinis, Andreas Eleutheriades, Kathryn Davidson and David Sugden
Affiliation:
Keywords: Substituted 4-fluoroindoles, synthesis, melatoninergic activity
Abstract: A series of new C-3 and N1-substituted 4-fluorotryptamides have been prepared and tested for their ability to activate pigment granule aggregation in Xenopus laevis melanophores and bind to the recombinant human MT1 and MT2 melatonin receptor subtypes expressed in NIH 3T3 cells. Planar sp2 geometry at C-3-βC seems to decrease the population of the preferred conformation as it renders 4-fluoroindoles 4b-d weaker antagonists than their C-3-βC-unsubstituted congeners 3a-e. This effect is not preclusively linked with the C-3 region, as the same geometry around N1 (compounds 5a-c) similarly leads to weak antagonistic action. Last, the new C-3 substituted 4-fluorotryptamides presented herein are substantially more potent than their respective N-OMe functionalized congeners, previously reported.
Export Options
About this article
Cite this article as:
Tsotinis Andrew, Eleutheriades Andreas, Davidson Kathryn, Sugden David, Tsotinis Andrew, Eleutheriades Andreas, Davidson Kathryn and Sugden David, Design and Synthesis of New N1 and C3-Substituted 4-Fluoroindolic Melatoninergics, Current Drug Discovery Technologies 2007; 4 (3) . https://dx.doi.org/10.2174/157016307782109715
DOI https://dx.doi.org/10.2174/157016307782109715 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Genetic Insights into Sporadic Parkinson's Disease Pathogenesis
Current Genomics Astroglial Connexins in Neurological and Neuropsychological Disorders and Radiation Exposure
Current Medicinal Chemistry Heat Shock Proteins: Therapeutic Drug Targets for Chronic Neurodegeneration?
Current Pharmaceutical Biotechnology A Biomarker Combining Imaging and Neuropsychological Assessment for Tracking Early Alzheimer's Disease in Clinical Trials
Current Alzheimer Research A Comprehensive Investigation of Molecular Signatures and Pathways Linking Alzheimer’s Disease and Epilepsy <i>via</i> Bioinformatic Approaches
Current Alzheimer Research Phytochemicals in the Treatment of Alzheimer’s Disease: A Systematic Review
Current Drug Targets In Silico Analysis of Green Tea Polyphenols as Inhibitors of AChE and BChE Enzymes in Alzheimer’s Disease Treatment
CNS & Neurological Disorders - Drug Targets Mitochondrial Metabolism Modulation: A New Therapeutic Approach for Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Fibrillar β-Amyloid Impairs the Late Phase of Long Term Potentiation
Current Alzheimer Research Astrocytes: New Targets for the Treatment of Neurodegenerative Diseases
Current Pharmaceutical Design Effects of 8-Residue Beta Sheet Breaker Peptides on Aged Aβ40 – Induced Memory Impairment and Aβ40 Expression in Rat Brain and Serum Following Intraamygdaloid Injection
Current Alzheimer Research Evolution of Antipsychotic Intervention in the Schizophrenic Psychosis
Current Drug Targets Synthesis, Characterization and Potential Applications of Multifunctional PEO-PPOPEO- Magnetic Drug Delivery System
Current Medicinal Chemistry Entrainment of the Human Circadian Clock to the Light-Dark Cycle and its Impact on Patients in the ICU and Nursing Home Settings
Current Pharmaceutical Design Impact of Patient Knowledge of Hypertension Complications on Adherence to Antihypertensive Therapy
Current Hypertension Reviews On the Relationship Between the Light/Dark Cycle, Melatonin and Oxidative Stress
Current Pharmaceutical Design Editorial (Thematic Issue: Current and Perspective Therapeutic Strategies for Alzheimer's Disease)
Current Pharmaceutical Design Therapeutic Effects of Rivastigmine and Alfa-Lipoic Acid Combination in the Charles Bonnet Syndrome: Electroencephalography Correlates
Current Clinical Pharmacology Dementia Etiologies and Remedies in Traditional Persian Medicine; A Review of Medicinal Plants and Phytochemistry
Current Drug Metabolism Patents on Therapeutic and Cosmetic Applications of Bioactives of Crocus Sativus L. and their Production through Synthetic Biology Methods: A Review
Recent Patents on Biotechnology